147236-05-3

Basic information

• Product Name: [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
• CAS NO: 147236-05-3
• Molecular Formula: C₂₃H₂₇ClN₂O₇
• Molecular Weight: 478.9227
• Mol File: 147236-05-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 499.4°C at 760 mmHg
• Flash Point: 255.8°C
• Vapor Pressure: 8.61E-11mmHg at 25°C
• CAS DataBase Reference: [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)(147236-05-3)
• EPA Substance Registry System: [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)(147236-05-3)

Safety Data

• Hazardous Substances Data: 147236-05-3(Hazardous Substances Data)

Upstream product

• 53-86-1 [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid 
• 77-86-1 2-amino-2-hydroxymethyl-1,3-propanediol 

Relevant articles and documents

Preparation of a crystalline salt of indomethacin and tromethamine by hot melt extrusion technology

Although salt formation is the most ubiquitous and effective method of increasing the solubility and dissolution rates of acidic and basic drugs, it consumes large quantities of organic solvents and is a batch process. Herein, we show that the dissolution rate of indomethacin (a poorly water-soluble drug) can be increased by using hot melt extrusion of a 1:1 (mol/mol) indomethacin:tromethamine mixture to form a highly crystalline salt, the physicochemical properties of which are investigated in detail. Specifically, pH–solubility studies demonstrated that this salt exhibited a maximal solubility of 19.34 mg/mL (>1000 times that of pure indomethacin) at pH 8.19. A solvent evaporation technique was also used for salt formation. Spectroscopic analyses (infrared, nuclear magnetic resonance) of both; demonstrated, in situ salt formation with proton transfer. Powder X-ray diffraction and differential scanning calorimetry confirmed the crystalline nature of salts formed by both methods. Even though a number of amorphous salts of acidic drugs have been reported, the formation of a crystalline salt of an acidic drug by hot melt extrusion is completely unprecedented, which makes this study an important benchmark for the pharmaceutical production industry.

Salt metathesis for developing injectable supramolecular metallohydrogelators as a multi-drug-self-delivery system

Salt metathesis has been exploited to generate a series of non-steroidal anti-inflammatory drug (NSAID) based Zn(ii) metallohydrogels displaying both anti-inflammatory and anti-bacterial properties. Relatively low cytotoxicity, rheoreversibility and injec